Proqr Therapeutics (PRQR)

$2.16 +0.13 (6.40%)
Market Cap 213.58M
Revenue (ttm) 20.46M
Net Income (ttm) -30.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -146.82%
Debt to Equity Ratio 0.06
Volume 901,700
Avg Vol 460,282
Day's Range N/A - N/A
Shares Out 105.21M
Stochastic %K 89%
Beta 0.31
Analysts Strong Sell
Price Target $8.88

Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Re...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 88 166 7000
Address:
Zernikedreef 9, Leiden, Netherlands
LeftyT
LeftyT Jun. 25 at 8:23 PM
$NEUP Solid, steady progress here.... just what I like to see in long plays like this. Actually was my biggest gainer today, edging out $ALT and $PRQR which is tough to do. Adding to all 3 of these may be the next move.
1 · Reply
Stocks4thought
Stocks4thought Jun. 25 at 7:48 PM
$PRQR $LLY
0 · Reply
Trader030
Trader030 Jun. 25 at 7:44 PM
$PRQR why the spike in volume ?
0 · Reply
skeezbag
skeezbag Jun. 25 at 6:50 PM
$PRQR hurry up and tuck it in $LLY
1 · Reply
FutureInvesting777
FutureInvesting777 Jun. 24 at 2:27 PM
$PRQR can it hold the forbidden 2+?
1 · Reply
valueforme
valueforme Jun. 23 at 7:49 AM
$PRQR More presentations coming. RNA Editing summit, July 29-31, 2025 | Boston, MA Platenburg: Pioneering RNA Modification Beyond Rare Diseases by Exploring Novel Editing Technologies & Targeting Multiple Mutations to Remove the Barriers to Treating Common Diseases Beal: Structure-Guided Optimization of ADAR-Guiding Oligonucleotides www.rnaediting-summit.com
1 · Reply
valueforme
valueforme Jun. 19 at 6:07 AM
$PRQR De Boer, wake up. If you keep missing timelines you communicated to investors, you will stay in this below 2 buck zone forever. You owe us CTA submission update
5 · Reply
FutureInvesting777
FutureInvesting777 Jun. 18 at 8:05 PM
$PRQR the forbidden zone (above 2) :) :
0 · Reply
Buylowfordoe
Buylowfordoe Jun. 17 at 3:40 PM
$ARWR $ALT $PRQR $ANVS
0 · Reply
LeftyT
LeftyT Jun. 17 at 3:38 PM
$ARWR $ALT $PRQR $ANVS CEO's of these companies all need to take note of this new FDA initiative: National Priority Voucher program, may make historical changes in time to market speed for innovative drugs that address large unmet needs... such as Alzheimer's, Parkinson's, and MASH. Giddyup folks!
2 · Reply
Latest News on PRQR
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025, 8:00 AM EDT - 6 weeks ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

ProQR Announces First Quarter 2025 Operating and Financial Results

May 8, 2025, 7:00 AM EDT - 6 weeks ago

ProQR Announces First Quarter 2025 Operating and Financial Results

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 2, 2025, 8:00 AM EDT - 7 weeks ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

May 1, 2025, 8:00 AM EDT - 7 weeks ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Apr 14, 2025, 7:00 AM EDT - 2 months ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

ProQR Announces Year End 2024 Operating and Financial Results

Mar 13, 2025, 7:00 AM EDT - 3 months ago

ProQR Announces Year End 2024 Operating and Financial Results

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Dec 10, 2024, 8:00 AM EST - 7 months ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 25, 2024, 4:45 PM EDT - 8 months ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 8 months ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 22, 2024, 4:01 PM EDT - 8 months ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Oct 7, 2024, 8:00 AM EDT - 9 months ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 4:30 PM EDT - 10 months ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

May 11, 2024, 5:57 PM EDT - 1 year ago

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

ProQR Announces First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2024 Operating and Financial Results

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 23, 2024, 7:00 AM EDT - 1 year ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 22, 2024, 4:31 PM EDT - 1 year ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Apr 19, 2024, 7:00 AM EDT - 1 year ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

ProQR Announces Year End 2023 Operating and Financial Results

Mar 13, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2023 Operating and Financial Results

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 19, 2024, 7:00 AM EST - 1 year ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Jan 5, 2024, 7:00 AM EST - 1 year ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Dec 8, 2023, 7:30 AM EST - 1 year ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 7, 2023, 7:00 AM EST - 1 year ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Nov 6, 2023, 7:00 AM EST - 1 year ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 28, 2023, 8:00 AM EDT - 1 year ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 8:00 AM EDT - 1 year ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 3, 2023, 7:00 AM EDT - 2 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Aug 1, 2023, 7:00 AM EDT - 2 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

ProQR: Too Many Failures For Its RNA Technology

Jul 9, 2023, 6:53 AM EDT - 2 years ago

ProQR: Too Many Failures For Its RNA Technology

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

Jul 6, 2023, 7:00 AM EDT - 2 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

May 9, 2023, 8:00 AM EDT - 2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

ProQR Announces Upcoming Investor Conferences in April and May

Apr 20, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Upcoming Investor Conferences in April and May

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Apr 18, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Mar 29, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Mar 14, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

ProQR to Present at Upcoming Scientific and Industry Conferences

Mar 7, 2023, 8:00 AM EST - 2 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

ProQR's stock jumps on expanded RNA deal with Lilly

Dec 22, 2022, 9:12 AM EST - 2 years ago

ProQR's stock jumps on expanded RNA deal with Lilly

LLY

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Dec 22, 2022, 6:15 AM EST - 2 years ago

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Lilly and ProQR to Expand RNA Editing Collaboration

Dec 22, 2022, 6:00 AM EST - 2 years ago

Lilly and ProQR to Expand RNA Editing Collaboration

LLY

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

Nov 14, 2022, 4:30 PM EST - 2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

ProQR Announces Third Quarter 2022 Operating and Financial Results

Nov 9, 2022, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2022 Operating and Financial Results

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Aug 11, 2022, 7:00 AM EDT - 3 years ago

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

Jun 1, 2022, 7:00 AM EDT - 3 years ago

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

May 9, 2022, 7:00 AM EDT - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

ProQR Announces First Quarter 2022 Operating and Financial Results

May 5, 2022, 4:30 PM EDT - 3 years ago

ProQR Announces First Quarter 2022 Operating and Financial Results

ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022

Apr 26, 2022, 4:10 PM EDT - 3 years ago

ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022

ProQR to Participate in the Kempen Life Sciences Conference

Apr 19, 2022, 4:30 PM EDT - 3 years ago

ProQR to Participate in the Kempen Life Sciences Conference

ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce

Apr 13, 2022, 10:00 AM EDT - 3 years ago

ProQR Therapeutics Pulls Plug On Inherited Retinal Disease Programs, Cuts 30% Workforce

ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

Apr 13, 2022, 7:00 AM EDT - 3 years ago

ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

Apr 4, 2022, 7:00 AM EDT - 3 years ago

ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit

ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

Mar 23, 2022, 4:30 PM EDT - 3 years ago

ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit

LeftyT
LeftyT Jun. 25 at 8:23 PM
$NEUP Solid, steady progress here.... just what I like to see in long plays like this. Actually was my biggest gainer today, edging out $ALT and $PRQR which is tough to do. Adding to all 3 of these may be the next move.
1 · Reply
Stocks4thought
Stocks4thought Jun. 25 at 7:48 PM
$PRQR $LLY
0 · Reply
Trader030
Trader030 Jun. 25 at 7:44 PM
$PRQR why the spike in volume ?
0 · Reply
skeezbag
skeezbag Jun. 25 at 6:50 PM
$PRQR hurry up and tuck it in $LLY
1 · Reply
FutureInvesting777
FutureInvesting777 Jun. 24 at 2:27 PM
$PRQR can it hold the forbidden 2+?
1 · Reply
valueforme
valueforme Jun. 23 at 7:49 AM
$PRQR More presentations coming. RNA Editing summit, July 29-31, 2025 | Boston, MA Platenburg: Pioneering RNA Modification Beyond Rare Diseases by Exploring Novel Editing Technologies & Targeting Multiple Mutations to Remove the Barriers to Treating Common Diseases Beal: Structure-Guided Optimization of ADAR-Guiding Oligonucleotides www.rnaediting-summit.com
1 · Reply
valueforme
valueforme Jun. 19 at 6:07 AM
$PRQR De Boer, wake up. If you keep missing timelines you communicated to investors, you will stay in this below 2 buck zone forever. You owe us CTA submission update
5 · Reply
FutureInvesting777
FutureInvesting777 Jun. 18 at 8:05 PM
$PRQR the forbidden zone (above 2) :) :
0 · Reply
Buylowfordoe
Buylowfordoe Jun. 17 at 3:40 PM
$ARWR $ALT $PRQR $ANVS
0 · Reply
LeftyT
LeftyT Jun. 17 at 3:38 PM
$ARWR $ALT $PRQR $ANVS CEO's of these companies all need to take note of this new FDA initiative: National Priority Voucher program, may make historical changes in time to market speed for innovative drugs that address large unmet needs... such as Alzheimer's, Parkinson's, and MASH. Giddyup folks!
2 · Reply
valueforme
valueforme Jun. 17 at 1:00 AM
$PRQR One more Lilly collaboratior https://www.ft.com/content/53d021c9-d15f-4471-86ef-e9abfc3ae7db
1 · Reply
FutureInvesting777
FutureInvesting777 Jun. 13 at 4:42 PM
$PRQR the forbidden zone beyond 2 :) :)
1 · Reply
johnnygogogo
johnnygogogo Jun. 12 at 6:54 PM
$PRQR Twitter feed getting more active again recently, fyi. Company also tends to like Friday announcements (if past is any indication).
0 · Reply
ehpats
ehpats Jun. 12 at 6:45 PM
$PRQR just need 100% gain from here and we will be back to where we should be. 😂
1 · Reply
dirkfrank
dirkfrank Jun. 10 at 8:55 PM
$PRQR the after hours champion 🥴
1 · Reply
biochirp
biochirp Jun. 10 at 1:35 PM
$PRQR should bounce with $XBI
0 · Reply
FutureInvesting777
FutureInvesting777 Jun. 6 at 5:18 PM
$PRQR slow and low levels accumulations ?!!
0 · Reply
Ekda
Ekda Jun. 5 at 3:36 PM
$PRQR over 2$ is coming soon in my opinion. steady up move continues
2 · Reply
LeftyT
LeftyT Jun. 4 at 3:56 PM
$PRQR Some think this early research stage is "nothingness" while others understand there is a critical foundation of targeting technic and clean toxicology support being produced. Patient investors will be building their positions here and continue to average up during dips while that foundation is being built. Looking forward to seeing clinical biomarker data by the end of the year. That's when the excitement and interest level with really take off. GLTA longs!!!
2 · Reply
Market_Max
Market_Max Jun. 3 at 7:54 PM
$PRQR Back in April I said this; I wasn't aware a major shareholder was about to reveal their similar feelings as well. Shareholders are about to sleep for another year of nothingness ...
1 · Reply
FutureInvesting777
FutureInvesting777 Jun. 3 at 4:34 PM
$PRQR do we need to go back to 1.20 and below ? :). This is Excruciating :) :) :) Van Herk “are” right !!!
1 · Reply
Benitocalixto
Benitocalixto Jun. 3 at 12:13 PM
$PRQR heading over to the shareholder meeting in about an hour
1 · Reply